4.5 Article

MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer

期刊

CANCER BIOLOGY & THERAPY
卷 20, 期 8, 页码 1113-1120

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/15384047.2019.1595285

关键词

Triple-negative breast cancer; tumor suppressor; miRNA; epithelial-mesencyhmal transition

类别

资金

  1. National Cancer Institute [CA165707]
  2. National Center for Advancing Translational Sciences [UL1TR000157, 1UL1TR001430]
  3. School of Medicine, Boston University [Genome Science Institute Seed Grant]

向作者/读者索取更多资源

Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer with poor prognosis due to lack of druggable targets such as hormone and growth factor receptors. Therefore, identification of targetable regulators such as miRNAs could provide new avenues for therapeutic applications. Here, we report that the expression of miR-4417 is suppressed during the progression of TNBC cells from non-malignant to the malignant stage. MiR-4417 is localized to chromosome 1p36, a region with high frequency of loss of heterozygosity in multiple cancers, and its biogenesis is DICER-dependent. Low expression of miR-4417 is significantly associated with worse prognosis in TNBC patients, while overexpression of miR-4417 is sufficient to inhibit migration and mammosphere formation of TNBC cells in vitro. Overall, our findings suggest miR-4417 exerts a tumor suppressive effect and thereby could serve as a prognostic biomarker and therapeutic tool against TNBC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据